Suspended since September 2015
| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| Referral date | 01 November 2008 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Paul Cooney |
| Executive Lead: | TBC |
| Project manager: | Jeremy Powell |
| Technical Lead: | TBC |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 January 2023 | Discontinued. Suspended since September 2015 |
| 08 October 2015 | Suspended. Following on from advice received from the company, there are no further plans to continue the development programme for fingolimod in primary-progressive multiple sclerosis. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
| 19 October 2011 |
Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established. |
For further information on our processes and methods, please see our CHTE processes and methods manual